NEW YORK, Dec. 15 (GenomeWeb News) - TriLink Bio Technologies has received an STTR Phase II funding from the National Institutes of Health to continue collaborating on the structure-free DNA and RNA program, the company said today.
Company spokesperson Kim Hampson told GenomeWeb News that the award is for $749,405 and will cover the period from January 2006 to Dec. 31, 2007.
TriLink is working with Howard Gamper of Thomas Jefferson University on the project, titled "Reagents for Preparing Structure-Free DNA and RNA." In Phase I, they demonstrated that certain base analogs can enhance accessibility of the pseudo-complementary target sequence to short probes.
The second phase of the project aims to improve the efficiency of hybridization between short oligonucleotide probes and long DNA and RNA targets, the company said.
In this collaboration, TriLink is developing the structure-free DNA and RNA technology while Gamper identifies the best nucleotide candidates which can be enzymatically incorporated into pseudo-complementary nucleic acid targets for improved hybridization performance.
The initial funding was for $99,871 from NIH and covered July to December.